LILRB1/CD85j/ILT2, His, Cynomolgus
LILRB1/CD85j/ILT2, His, Cynomolgus

Immobilized LILRB1/CD85j/ILT2, His, Cynomolgus, His Tag at 2 μg /ml (100 μl/well) on the plate. Dose response curve for Anti-LILRB1 Antibody, hFc Tag with the EC50 of 9.6ng/ml determined by ELISA.

LILRB1/CD85j/ILT2, His, Cynomolgus

The purity of LILRB1/CD85j/ILT2, His, Cynomolgus is greater than 95% as determined by SEC-HPLC.

LILRB1/CD85j/ILT2, His, Cynomolgus

LILRB1/CD85j/ILT2, His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

LILRB1/CD85j/ILT2, His, Cynomolgus

LILRB1, also known as CD85j and ILT2, is a 110 kDa transmembrane glycoprotein in the LILR immunoregulatory protein family. Mature human LILRB1 consists of a 438 amino acid (aa) extracellular domain (ECD) with 4 tandem Ig-like domains, a 21 aa transmembrane segment, and a 168 aa cytoplasmic domain with 4 inhibitory ITIM motifs.LILRB1 is a receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles. Receptor for H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand binding results in inhibitory signals and down-regulation of the immune response.
Z04857
¥72,752.00

Ask us a question
Product Introduction
Species Cynomolgus
Protein Construction
LILRB1/CD85j/ILT2 (Gly41-His474)
Accession # XP_045236898.1		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 48.19 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 60-80 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • LILRB1/CD85j/ILT2, His, Cynomolgus
    • LILRB1/CD85j/ILT2, His, Cynomolgus

    Immobilized LILRB1/CD85j/ILT2, His, Cynomolgus, His Tag at 2 μg /ml (100 μl/well) on the plate. Dose response curve for Anti-LILRB1 Antibody, hFc Tag with the EC50 of 9.6ng/ml determined by ELISA.

  • LILRB1/CD85j/ILT2, His, Cynomolgus
    • LILRB1/CD85j/ILT2, His, Cynomolgus

    The purity of LILRB1/CD85j/ILT2, His, Cynomolgus is greater than 95% as determined by SEC-HPLC.

  • LILRB1/CD85j/ILT2, His, Cynomolgus
    • LILRB1/CD85j/ILT2, His, Cynomolgus

    LILRB1/CD85j/ILT2, His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background LILRB1, also known as CD85j and ILT2, is a 110 kDa transmembrane glycoprotein in the LILR immunoregulatory protein family. Mature human LILRB1 consists of a 438 amino acid (aa) extracellular domain (ECD) with 4 tandem Ig-like domains, a 21 aa transmembrane segment, and a 168 aa cytoplasmic domain with 4 inhibitory ITIM motifs.LILRB1 is a receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles. Receptor for H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand binding results in inhibitory signals and down-regulation of the immune response.
Synonyms ILT2; ILT-2; ILT2FLJ37515; LILRB1; LIR1; MIR7; CD85J; XXbac-BCX85G21.4

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.